Beyond Air Provides LungFit® PH System to U.S. Naval Hospital Guam for Neonatal Critical Care in Partnership with TrillaMed
Beyond Air, Inc. (NASDAQ: XAIR) has deployed its LungFit® PH system to the U.S. Naval Hospital Guam for neonatal critical care, in partnership with TrillaMed. The LungFit® PH system generates Nitric Oxide (NO) from room air to treat persistent pulmonary hypertension in neonates (PPHN). Key features include a portable design, advanced NO generating technology, and easy integration into hospital infrastructure.
The U.S. Naval Hospital Guam serves over 17,000 active-duty military personnel and family members, with an expected increase of 2,500 in the next two years. The hospital currently delivers an average of 315 babies per year, projected to rise to 487 births by 2033. This deployment demonstrates the hospital's commitment to utilizing advanced technologies in neonatal care for military families.
Beyond Air, Inc. (NASDAQ: XAIR) ha distribuito il suo sistema LungFit® PH presso l'Ospedale Navale degli Stati Uniti a Guam per cure neonatali critiche, in collaborazione con TrillaMed. Il sistema LungFit® PH genera Ossido Nitrico (NO) dall'aria ambiente per trattare l'ipertensione polmonare persistente nei neonati (PPHN). Le caratteristiche principali includono un design portatile, tecnologia avanzata per la generazione di NO e facile integrazione nell'infrastruttura ospedaliera.
L'Ospedale Navale degli Stati Uniti a Guam serve oltre 17.000 personale militare in servizio attivo e i loro familiari, con un atteso aumento di 2.500 nei prossimi due anni. Attualmente, l'ospedale assiste in media 315 nascite all'anno, prevedendo un aumento a 487 nascite entro il 2033. Questa distribuzione dimostra l'impegno dell'ospedale nell'utilizzare tecnologie avanzate per le cure neonatali per le famiglie militari.
Beyond Air, Inc. (NASDAQ: XAIR) ha desplegado su sistema LungFit® PH en el Hospital Naval de los EE. UU. en Guam para cuidado crítico neonatal, en colaboración con TrillaMed. El sistema LungFit® PH genera Óxido Nítrico (NO) del aire ambiente para tratar la hipertensión pulmonar persistente en neonatos (PPHN). Las características clave incluyen un diseño portátil, tecnología avanzada para la generación de NO y fácil integración en la infraestructura del hospital.
El Hospital Naval de los EE. UU. en Guam atiende a más de 17,000 militares en servicio activo y sus familiares, con un aumento previsto de 2,500 en los próximos dos años. Actualmente, el hospital entrega un promedio de 315 bebés por año, proyectándose que aumente a 487 nacimientos para 2033. Este despliegue demuestra el compromiso del hospital con la utilización de tecnologías avanzadas en el cuidado neonatal para las familias militares.
비욘드 에어 주식회사 (NASDAQ: XAIR)는 트릴라메드(TrillaMed)와 협력하여 미국 해군 병원 괌에 롱핏® PH 시스템을 배치하여 신생아 중환자 치료를 제공했습니다. 롱핏® PH 시스템은 방대한 공기에서 질소 산화물(NO)을 생성하여 신생아 지속성 폐 고혈압(PPHN)을 치료합니다. 주요 기능으로는 휴대 가능 디자인, 최첨단 NO 생성 기술, 병원 인프라에의 용이한 통합이 있습니다.
미국 해군 병원 괌은 17,000명 이상의 현역 군인과 그 가족을 치료하며, 향후 2년 동안 2,500명이 증가할 것으로 예상됩니다. 이 병원은 현재 연평균 315명의 아기를 출산하고 있으며, 2033년까지 487명의 출산으로 증가할 것으로 예상됩니다. 이번 배치는 군 가족을 위한 신생아 치료에 있어 첨단 기술의 활용에 대한 병원의 의지를 보여줍니다.
Beyond Air, Inc. (NASDAQ: XAIR) a déployé son système LungFit® PH à l'hôpital naval des États-Unis à Guam pour des soins critiques néonatals, en partenariat avec TrillaMed. Le système LungFit® PH génère de l'oxyde nitrique (NO) à partir de l'air ambiant pour traiter l'hypertension pulmonaire persistante chez les nouveau-nés (PPHN). Les principales caractéristiques comprennent un design portable, une technologie avancée de génération de NO et une intégration facile dans l'infrastructure de l'hôpital.
L'hôpital naval des États-Unis à Guam sert plus de 17 000 militaires en service actif et leurs familles, avec une augmentation prévue de 2 500 dans les deux prochaines années. L'hôpital délivre actuellement en moyenne 315 bébés par an, ce qui devrait augmenter à 487 naissances d'ici 2033. Ce déploiement démontre l'engagement de l'hôpital à utiliser des technologies avancées dans les soins néonatals pour les familles militaires.
Beyond Air, Inc. (NASDAQ: XAIR) hat sein LungFit® PH-System im US Navy Krankenhaus Guam für neonatale Intensivpflege in Zusammenarbeit mit TrillaMed bereitgestellt. Das LungFit® PH-System erzeugt Stickstoffmonoxid (NO) aus Raumluft, um persistierende pulmonale Hypertonie bei Neugeborenen (PPHN) zu behandeln. Zu den Hauptmerkmalen gehören ein tragbares Design, fortschrittliche NO-Erzeugungstechnologie und einfache Integration in die Krankenhausinfrastruktur.
Das US Navy Krankenhaus Guam versorgt über 17.000 aktive Militärangehörige und deren Familien, mit einem erwarteten Anstieg von 2.500 in den nächsten zwei Jahren. Das Krankenhaus entbindet derzeit jährlich durchschnittlich 315 Babys, was bis 2033 auf 487 Geburten steigen soll. Diese Bereitstellung zeigt das Engagement des Krankenhauses, fortschrittliche Technologien in der neonatologischen Versorgung für Militärfamilien zu nutzen.
- Deployment of LungFit® PH system to U.S. Naval Hospital Guam expands market reach
- Partnership with TrillaMed enhances distribution capabilities
- Potential for increased usage as U.S. Naval Hospital Guam's birth rate is expected to rise from 315 to 487 by 2033
- None.
Insights
The deployment of Beyond Air's LungFit® PH system to the U.S. Naval Hospital Guam is a positive development for the company, albeit with immediate financial impact. This partnership demonstrates the growing adoption of Beyond Air's technology in critical care settings, particularly for neonatal patients.
The system's key features, including its portability and advanced NO generating technology, address important needs in neonatal intensive care. With the U.S. Naval Hospital Guam delivering an average of 315 babies per year, projected to increase to 487 by 2033, there's potential for consistent utilization of the LungFit® PH system.
While this single deployment may not significantly impact Beyond Air's financials in the short term, it serves as a strategic foothold in military healthcare facilities. This could pave the way for broader adoption across other naval hospitals or military medical centers, potentially leading to larger contracts in the future.
GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, is proud to announce the deployment of its groundbreaking LungFit® PH system to the U.S. Naval Hospital Guam. This partnership, made possible through collaboration with TrillaMed, marks a significant advancement in the neonatal critical care unit, offering enhanced care for newborns in need of respiratory support.
The LungFit® PH system is an innovative device designed to generate Nitric Oxide (NO) from room air and deliver NO for the treatment of persistent pulmonary hypertension in neonates (PPHN), a condition that affects the lungs and heart of newborns. The system provides a safe, efficient, and user-friendly solution to address critical respiratory conditions, ensuring that the hospital’s youngest and most vulnerable patients receive the highest standard of care.
Key Features of the LungFit® PH System:
- Portable and compact design, making it ideal for intensive care settings
- Advanced nitric oxide generating technology with no need for high-pressure cylinders
- Rapid response for improved oxygenation in neonates with PPHN
- Easy integration into existing hospital infrastructure
"We are honored to support the U.S. Naval Hospital Guam in their mission to provide top-tier neonatal care," said Steve Lisi, CEO of Beyond Air. "Through our partnership with TrillaMed, we are able to extend the reach of our LungFit® PH, delivering critical solutions to the healthcare community. This collaboration is a testament to our commitment to advancing neonatal care and improving patient outcomes."
The U.S. Naval Hospital Guam serves as a critical care provider for the military community in the region. More than 17,000 active-duty military personnel and family members currently are stationed on Guam, which is expected to increase by 2,500 in the next two years. The U.S. Naval Hospital Guam delivers an average of 315 babies per year, with that number expected to rise to 487 births by 2033. The introduction of the LungFit® PH system underscores the hospital's dedication to utilizing state-of-the-art technologies in neonatal care, ensuring military families have access to the latest in respiratory treatment options.
About Beyond Air®, Inc.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first system, LungFit® PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. For more information, visit www.beyondair.net.
About LungFit®*
Beyond Air’s LungFit is a cylinder-free, phasic flow generator and delivery system and has been designated as a medical device by the U.S. Food and Drug Administration (FDA). The ventilator compatible version of the device can generate NO from ambient air on demand for delivery to the lungs at concentrations ranging from 1 ppm to 80 ppm. The LungFit system could potentially replace large, high-pressure NO cylinders providing significant advantages in the hospital setting, including greatly reducing inventory and storage requirements, improving overall safety with the elimination of NO2 purging steps, and other benefits. LungFit can also deliver NO at concentrations at or above 80 ppm for potentially treating severe acute lung infections in the hospital setting (e.g. COVID-19, bronchiolitis) and chronic, refractory lung infections in the home setting (e.g. NTM). With the elimination of cylinders, Beyond Air intends to offer NO treatment in the home setting.
* Beyond Air’s LungFit PH is approved for commercial use only in the United States of America to treat term and near-term neonates with hypoxic respiratory failure. Beyond Air’s other LungFit systems are not approved for commercial use and are for investigational use only. Beyond Air is not suggesting NO use over 80 ppm or use at home.
About Nitric Oxide
Nitric Oxide is a powerful molecule, naturally synthesized in the human body, proven to play a critical role in a broad array of biological functions. In the airways, NO targets the vascular smooth muscle cells that surround the small resistance arteries in the lungs. Currently, exogenous inhaled NO is used in adult respiratory distress syndrome, post certain cardiac surgeries and persistent pulmonary hypertension of the newborn to treat hypoxemia. Additionally, NO is believed to play a key role in the innate immune system and in vitro studies suggest that NO possesses anti-microbial activity not only against common bacteria, including both gram-positive and gram-negative, but also against other diverse pathogens, including mycobacteria, viruses, fungi, yeast and parasites, and has the potential to eliminate multi-drug resistant strains.
About TrillaMed.
TrillaMed is a premier provider of medical supplies and technologies to government and healthcare systems globally. As a trusted partner, TrillaMed delivers best-in-class solutions to meet the critical needs of healthcare providers, ensuring military personnel and their families receive the highest level of care.
CONTACTS:
Investor Relations contacts
Corey Davis, Ph.D.
LifeSci Advisors, LLC
Cdavis@lifesciadvisors.com
(212) 915-2577
FAQ
What is the LungFit® PH system deployed by Beyond Air (XAIR) to U.S. Naval Hospital Guam?
How many babies does U.S. Naval Hospital Guam deliver annually, and how is this expected to change?
What are the key features of Beyond Air's (XAIR) LungFit® PH system?
